SC: Issues Contempt Notice To Ramdev Led Patanjali Ayurved For False Adv.
NEW DELHI : The Supreme Court today came own heavily on the Centre in connection with the Patanjali Ayurved “misleading and false” advertisement case.”The government is sitting with its eye closed,” the Supreme Court said.
Previously, on November 21, 2023, the Court reprimanded Patanjali Ayurved for continuing to publish misleading claims and advertisements against modern systems of medicine. Justice Amanullah went on to issue a stern warning of imposing a cost of Rs 1 Crore in case such advertisements are continued. The Top Court had cautioned Patanjali Ayurved, co-owned by Yoga Guru Ramdev, against making “false” and “misleading” claims in advertisements about its medicines.
“What happened to this Guru Swami Ramdev Baba?…
Ultimately we respect him as he popularised yoga. We all go for this. But, he should not criticise the other system. The Indian Medical Association (IMA) had referred to several advertisements which allegedly projected the allopathy and the doctors in poor light, saying that “disparaging” statements have also been made by firms, engaged in the production of ayurvedic medicines, to mislead the general public.
These commercials say that the medical practitioners themselves are dying despite taking modern medicines, the counsel for the IMA had said. You see the type of advertisements accusing all the doctors as if they are killers or something. Huge advertisements (have been given),” the bench headed by the then CJI NV Ramana, since retired, had said
Earlier the top court had asked the counsel appearing for the Centre to find a remedy to the issue of misleading medical advertisements. The Supreme Court was listening to petitions filed by the Indian Medical Association (IMA), when Justices Ahsanuddin Amanullah and Prashant Kumar Mishra issued a stern warning to the company co-founded by Baba Ramdev. “All such false and misleading advertisements of Patanjali Ayurveda have to stop immediately.
The Court will take any such infraction very seriously, and the Court will also consider imposing costs to the extent of Rs. 1 crores on every product regarding which a false claim is made that it can “cure” a particular disease,” Livelaw quoted Justice Amanullah saying.
